High Risk of Cardiovascular Mortality in Individuals With Impaired Fasting Glucose Is Explained by Conversion to Diabetes

The Hoorn Study

JOSINA M. RIJKELIJKHUIZEN, PHD[1]
GIEL NIJPELS, MD, PHD[1,2]
ROBERT J. HEINE, MD, PHD[1,3]
LEX M. BOUTER, PHD[1]
COEN D.A. STEHOUWER, MD, PHD[1,4]
JACQUELINE M. DEKKER, PHD[1]

OBJECTIVE — To optimize identification of future diabetic patients, the American Diabetes Association (ADA) introduced criteria for impaired fasting glucose (IFG) in 1997 (IFG 6.1 mmol/l [IFG6.1]) and lowered the threshold from 6.1 to 5.6 mmol/l (IFG5.6) in 2003. Our aim was to assess the consequences of lowering the IFG cutoff on the risk of cardiovascular disease (CVD) mortality and to evaluate whether this risk is explained by a conversion to type 2 diabetes within 6.4 years.

RESEARCH DESIGN AND METHODS — In a population-based cohort, the Hoorn Study, plasma glucose was determined in 1989 and 1996 ($n = 1,428$). Subjects were classified in 1989 according to 1997 and 2003 ADA criteria. Subjects with IFG in 1989 were further classified according to diabetes status in 1996. Hazard ratios for CVD mortality ($n = 81$) in the period 1996–2005 were adjusted for age and sex.

RESULTS — Subjects with IFG6.1, but not IFG5.6, had a significantly higher CVD mortality risk than normal fasting glucose (NFG) subjects. Subjects who converted from IFG to diabetes (IFG6.1: 42%; IFG5.6: 21%) had a more than twofold risk of CVD mortality (IFG6.1: 2.47 [1.17–5.19]; IFG5.6: 2.14 [1.12–4.10]) than subjects with NFG. IFG subjects who did not develop diabetes did not have significantly higher CVD mortality risks (IFG6.1: 1.50 [0.72–3.15]; IFG5.6: 1.15 [0.69–1.93]).

CONCLUSIONS — The lower cutoff for IFG (ADA 2003 criteria) results in a category of IFG that no longer represents a high-risk state of CVD. Furthermore, only subjects who convert from IFG to diabetes have a high risk of CVD mortality.

Impaired glucose regulation is a high-risk state for type 2 diabetes and cardiovascular disease (CVD) (1). Impaired glucose regulation can be either impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), i.e., elevated glucose levels 2 h after the 75-g oral glucose tolerance test (OGTT). Both conditions contribute independently to the high risk of diabetes and CVD but show limited agreement (2,3). When the American Diabetes Association (ADA) introduced fasting diagnostic criteria in 1997 to avoid the OGTT (4), which is not commonly used in clinical practice, the cutoff for IFG was set at 6.1 mmol/l (IFG6.1). In 2003, the ADA decided that this value should be lowered from 6.1 to 5.6 mmol/l (IFG5.6) (5). This new cutoff for the definition of IFG was selected as the level of fasting glucose with the optimal sensitivity and specificity to predict incident diabetes in four population studies, including the Hoorn Study. However, the consequences of lowering the fasting glucose cutoff in the definition of IFG for the risk of CVD were not evaluated. Because prevention programs at present are targeted at impaired glucose regulation to avoid both diabetes as well as CVD, this point needs to be addressed. Thus, does IFG confer a high-risk state of CVD, even in individuals who do not develop diabetes at a later stage? For IGT, it has been shown that the elevated CVD risk was also present in subjects who remained IGT or returned to normal glucose tolerance (6). Such information is not yet available for subjects with IFG.

The aims of the present study were *1*) to assess the impact of lowering the IFG cutoff on the prevalence of IFG and the incidence of diabetes among subjects classified as IFG in 1989, 2) to assess the impact of lowering the IFG cutoff on the associated risk of all-cause and CVD mortality, and 3) to study if the association between IFG and the risk of all-cause and CVD mortality is independent of the conversion to diabetes during follow-up.

RESEARCH DESIGN AND METHODS

Study population
The Hoorn Study is a population-based cohort study of glucose intolerance in a general Dutch population, which started in 1989. The study design has been described in detail elsewhere (7). The study cohort consisted of 2,484 Caucasian men and women in 1989. A follow-up examination was performed between January 1996 and December 1998 (mean follow-up duration was 6.4 years). Of the

initial cohort, 150 subjects had died and 108 subjects had moved out of Hoorn. A total of 140 other subjects were not invited because of logistic reasons. Of the remaining 2,086 subjects, 1,513 participated in the follow-up study in 1996. Details of this follow-up study have been described previously (3). All subjects have been followed with respect to mortality. The study was approved by the Ethics Committee of the VU University Medical Center. Informed consent was obtained from all participants.

Glucose intolerance classification

Both in 1989 and 1996, a 75-g OGTT was administered after an overnight fast. Fasting plasma glucose (FPG) and 2-h postload plasma glucose levels were determined with a glucose dehydrogenase method (Merck, Darmstadt, Germany) in 1989 and with the hexokinase method (Boehringer Mannheim, Mannheim, Germany) in 1996. Subjects ($n = 41$) who had already been using insulin, blood glucose–lowering agents, or a diet for diabetes were marked as "known diabetes mellitus" and were excluded from the analyses. Furthermore, 44 subjects were excluded because of missing information of plasma glucose values. Therefore, the analyses in the present study were performed on 1,428 subjects who completed both the measurements in 1989 and 1996. The prevalence of IFG according to both the 1997 ADA criteria (IFG6.1: IFG with FPG 6.1–7.0 mmol/l) and 2003 ADA criteria (IFG5.6: IFG with FPG 5.6–7.0 mmol/l) was determined for 1989 and 1996. Furthermore, all subjects were classified with 1997 and 2003 ADA criteria as normal fasting glucose (NFG), impaired fasting glucose (IFG), or newly discovered diabetes according to their glucose status in 1989. For each set of criteria, for subjects with IFG status in 1989, we distinguished between individuals who had and who had not converted to diabetes at the follow-up examination in 1996–1998. For a timeline of the design of the present study, see Fig. 1.

Measurements

Weight and height were measured with subjects wearing underwear only. BMI was calculated as the ratio of weight and squared height. Waist and hip circumferences were measured according to a standardized procedure (8). Waist-to-hip ratio was defined as waist circumference divided by hip circumference. Triglycerides, total cholesterol, and HDL cholesterol were determined from fasting blood samples by enzymatic techniques (Boehringer Mannheim). The Friedewald formula was used to calculate the level of LDL cholesterol (9).

Follow-up of mortality

There is a continuous registration of the mortality of participants of the Hoorn Study performed in cooperation with the municipal registry of the city of Hoorn. Information about causes of death was extracted from medical records of general practitioners and the local hospital. Causes of death were coded according to the ICD-9 (10). Cardiovascular mortality was defined as ICD-9 codes 390–459 (diseases of the circulatory system) or 798 (sudden death, cause unknown), because sudden death is generally caused by CVD (11). The vital status of subjects who had moved out of Hoorn was obtained from the municipal registries of the cities to which they had moved. Follow-up data of the period from the physical examination in 1996 until 1 January 2005 were used to calculate CVD mortality risks (Fig. 1).

Statistical analysis

Relative risks of all-cause and CVD mortality during the period after the physical examination in 1996 were estimated by Cox proportional hazards analyses. For both 1997 and 2003 ADA diagnostic criteria, hazard ratios and 95% CIs for all-cause and CVD mortality were obtained for subjects with IFG status or diabetes relative to those with NFG status. Because this is a descriptive study, all models were adjusted for age and sex only. Values are presented as means ± SD. Statistical analyses were performed using standard software (SPSS 12.0.2). P values <0.05 were considered significant.

Figure 1—*Timeline of the study design. Subjects performed a first OGTT in 1989 and a second in 1996. The prevalence of IFG5.6 and IFG6.1 was obtained both in 1989 and 1996. Subjects were classified according the 1997 and 2003 ADA criteria based on their first OGTT. Subjects with IFG5.6 or IFG6.1 in 1989 were classified again in 1996 to determine whether they had converted to diabetes or not. Follow-up data of cardiovascular mortality were used from 1996 until 2005. DM, diabetes.*

RESULTS — The characteristics of the population classified according to both 1997 and 2003 ADA criteria in 1989 are shown in Table 1. Subjects with IFG5.6 had a healthier profile than subjects with IFG6.1 (e.g., lower blood pressure and waist circumference). The prevalence of IFG5.6 was 33.2% (95% CI 30.8–35.6) and 10.1% (8.6–11.6) for IFG6.1. The mean FPG level of the study population was 5.6 ± 1.3 mmol/l in 1989 and, after a mean follow-up of 6.4 years, had increased to 6.2 ± 1.3 mmol/l in 1996. As a result, the prevalence of IFG5.6 increased to 55.7% (95% CI 53.2–58.2) and 25.6% (23.4–27.8) for IFG6.1.

Of the subjects with IFG6.1 in 1989, 42% had progressed to diabetes (Table 2) and the incidence rate was 66.5/1,000 person-years (95% CI 49.9–83.0). Of the IFG5.6 subjects, only 21% developed diabetes (Table 2), with an incidence rate 32.7/1,000 person-years (26.3–39.1).

In the period from the physical examination in 1996 until 1 January 2005, 192 subjects died. For 184 of the deceased (95.8%), the cause of death could be retrieved; 81 subjects died from CVD. Age- and sex-adjusted hazard ratios for all-cause and CVD mortality are shown in Table 3. The hazard ratio of CVD mortality for subjects with IFG6.1 was 1.87 (1.07–3.25) relative to the reference category with normal glucose levels (NFG). The hazard ratio for CVD mortality for the IFG5.6 group was lower and not statistically significant: 1.37 (0.87–2.16). The associations with all-cause mortality showed similar trends for both criteria: the all-cause and CVD mortality risks for subjects classified as IFG were both significantly higher than for NFG subjects and similar to the risks for newly detected diabetic subjects.

Table 1—*Characteristics of the population classified according to both 1997 and 2003 ADA criteria in 1989*

	1997 ADA criteria		2003 ADA criteria		Both criteria
	NFG	IFG	NFG	IFG	Type 2 diabetes
n	1,217	149	878	488	62
Age (years)	60.1 ± 6.8	62.5 ± 6.9	59.8 ± 6.9	61.5 ± 6.8	63.3 ± 6.9
Sex (% male)	44.5	54.4	41.6	52.7	54.8
Height (cm)	169.1 ± 8.6	169.1 ± 8.6	168.8 ± 8.7	169.6 ± 8.6	169.1 ± 9.3
Weight (kg)	74.7 ± 10.7	78.9 ± 11.2	73.7 ± 10.5	77.8 ± 10.9	82.3 ± 13.8
BMI (kg/m^2)	26.1 ± 3.1	27.6 ± 3.6	25.8 ± 3.0	27.0 ± 3.3	28.8 ± 4.0
Cholesterol (mmol/l)	6.6 ± 1.1	6.7 ± 1.1	6.5 ± 1.1	6.7 ± 1.1	6.6 ± 1.5
HDL cholesterol (mmol/l)	1.36 ± 0.37	1.30 ± 0.34	1.38 ± 0.37	1.30 ± 0.36	1.17 ± 0.30
LDL cholesterol (mmol/l)	4.6 ± 1.0	4.6 ± 1.1	4.5 ± 1.0	4.7 ± 1.0	4.5 ± 1.3
Triglycerides (mmol/l)	1.5 ± 0.8	1.7 ± 0.8	1.4 ± 0.7	1.7 ± 1.0	2.1 ± 1.0
Hip circumference (cm)	101.5 ± 6.2	102.8 ± 7.1	101.2 ± 6.01	102.4 ± 6.7	104.4 ± 7.1
Waist circumference (cm)	89.0 ± 10.0	95.2 ± 10.7	87.7 ± 9.8	93.2 ± 10.0	98.4 ± 11.1
Waist-to-hip ratio	0.88 ± 0.08	0.93 ± 0.07	0.87 ± 0.08	0.91 ± 0.08	0.94 ± 0.09
Diastolic blood pressure (mmHg)	81.4 ± 10.1	84.9 ± 9.7	80.6 ± 9.9	83.8 ± 10.2	85.5 ± 11.8
Systolic blood pressure (mmHg)	131.4 ± 19.2	144.5 ± 19.6	129.5 ± 18.2	138.9 ± 20.7	143.4 ± 17.3

Data are means ± SD unless otherwise indicated. Type 2 diabetes represents newly discovered type 2 diabetes.

When comparing subjects with IFG status in 1989 who did and who did not convert to diabetes in 1996, Cox regression revealed that the risks for all-cause and CVD mortality were not significantly higher than for NFG for subjects who had not converted to diabetes (Table 3). Subjects with IFG5.6 or IFG6.1 status who had converted to diabetes during the 6.4 years of follow-up had higher all-cause and CVD mortality risks than subjects who were classified as newly discovered diabetes in 1989 and had significantly (up to 2.5 times) higher all-cause and CVD mortality risks than subjects with normal glucose status at that time.

CONCLUSIONS — The present study showed that lowering the cutoff for IFG from 6.1 to 5.6 mmol/l increases the prevalence of IFG and reduces the incidence rate of diabetes. Furthermore, the hazard ratios of all-cause and cardiovascular mortality were lower for IFG5.6 than for IFG6.1. In addition, the association between IFG and the risk of all-cause and CVD mortality is only present in subjects who had converted to diabetes during follow-up.

Limitations of the study
A number of possible study limitations needs to be discussed. In this study, we used a subpopulation of the Hoorn Study. The baseline cohort of the Hoorn Study in 1989 was a random sample of the population of the municipality of Hoorn, aged 50–70 years. For both the examinations in 1989 and 1996, ~70% response was reached; this high rate of participation suggests good representativeness. In population studies, however, generally, participants are healthier than nonparticipants. Therefore, both the prevalence and the incidence of diabetes might be somewhat underestimated. A limitation of the present study is the small number of cases in the subgroups, thus limiting the power of our study. However, the large difference in the estimates of those who did and those who did not convert, along with the CIs, show a very clear picture. Furthermore, conclusions about conversion to diabetes and about mortality were based only on those subjects who survived the 6.4 years between the first (1989) and second (1996) physical examination. Thus, numbers of conversion and mortality may have been slightly higher. However, this is one of very few population studies with repeated glucose testing (after 6.4 years) and subsequently 10 years of follow-up of mortality.

Consequences of lowering the IFG cutoff for the prevalence of IFG and incidence rate of diabetes
We found a considerably higher prevalence of IFG5.6 than IFG6.1. Similar results have also been described by Borch-Johnsen et al. (12) and Davidson et al. (13), with IFG ranging from 24.1 to 38.8%. One of the reasons for proposing the 2003 ADA criteria was to increase sensitivity for the prediction of future diabetes. However, this is at the cost of specificity (5). According to our analyses, the fraction of IFG5.6 subjects developing diabetes decreased from 40 to 20% compared with IFG6.1. Vaccaro and Riccardi (14) studied the risk of progression from IFG to diabetes in the Italian Telephone Company (with a lower mean age than in our study) and found an even lower percentage of 12.5% when subjects were classified by 2003 ADA criteria. Thus, with the new criteria, the prevalence of IFG is increased considerably, while this is accompanied by a lower risk of future diabetes.

Table 2—*A 6.4-year change in glucose tolerance status of subjects classified as IFG in 1989*

	1997 ADA criteria	2003 ADA criteria
Conversion to NFG	28 (18.8)	33 (6.8)
Remained IFG	59 (39.6)	354 (72.5)
Conversion to type 2 diabetes	62 (41.6)	101 (20.7)
Total	149 (100)	488 (100)

Data are n (%).

Table 3—*Age- and sex-adjusted hazard ratios of all-cause and CVD mortality for glucose tolerance categories according to the 1997 and 2003 ADA criteria*

	Cutoff values/FPG (mmol/l)	n	Mortality (n)	CVD mortality (n)	All-cause mortality	CVD mortality
1997 ADA criteria						
NFG	<6.1	1,217	141	58	1	1
IFG (all)	6.1–7.0	149	34	16	1.71 (1.17–2.49)	1.87 (1.07–3.25)
IFG → IFG/ NFG		87	15	8	1.21 (0.71–2.06)	1.50 (0.72–3.15)
IFG → diabetes		62	19	8	2.54 (1.57–4.10)	2.47 (1.17–5.19)
New diabetes	≥7.0	62	17	7	1.81 (1.09–3.01)	1.72 (0.78–3.80)
2003 ADA criteria						
NFG	<5.6	878	92	39	1	1
IFG (all)	≥5.6 and <7.0	488	93	35	1.41 (1.04–1.89)	1.37 (0.87–2.16)
IFG → IFG/ NFG		387	55	23	1.18 (0.85–1.65)	1.15 (0.69–1.93)
IFG → diabetes		101	28	12	2.24 (1.46–3.43)	2.14 (1.12–4.10)
New diabetes	≥7.0	62	17	7	1.94 (1.15–3.27)	1.78 (0.79–4.00)

Data are hazard ratios (95% CI) unless otherwise indicated. NFG, normal fasting glucose (in 1989); IFG, impaired fasting glucose (in 1989); IFG → IFG/NFG, subjects classified as having IFG in 1989 and as having IFG or NFG in 1996; IFG → diabetes, subjects classified as having IFG in 1989 and as diabetic in 1996; New diabetes, newly discovered type 2 diabetes (in 1989).

Consequences of lowering the IFG cutoff for CVD risk

Several studies have shown that IGT is a risk factor for CVD mortality (6,15,16), but there is debate whether this is also true for IFG (17). Qiao et al. (6) reported that IGT is a risk predictor for CVD morbidity and mortality and for all-cause mortality independent of the development of overt diabetes. We and others have previously shown that high 2-h glucose after an OGTT is more closely associated with an adverse CVD risk profile and CVD risk (2,18). In the present study, we showed that optimizing the cutoff of IFG for identification of future diabetes does not correspond to the risk of all-cause and CVD mortality and that the CVD mortality risk of IFG subjects is only present in those who convert to diabetes. Subjects with IFG5.6 at baseline who had diabetes at follow-up had significantly lower HDL cholesterol and higher triglycerides, waist circumference, waist-to-hip ratio, and systolic blood pressure than subjects who did not have diabetes at follow-up (data not shown), indicating large differences in CVD risk profile between subjects who do and do not convert to diabetes. In subjects with IFG6.1, differences were smaller and only statistically significant for triglycerides levels (data not shown), indicating a more homogeneous group of IFG subjects with less relatively healthy subjects included.

We previously reported lower CVD mortality risk in subjects with FPG between 5.6 and 6.0 mmol/l (18). Now, with an even longer follow-up duration, we find that CVD mortality risk in the IFG5.6 group is not significantly higher than NFG subjects. Balkau et al. (19) reported J-shaped relationships with fasting glucose concentrations and all-cause mortality in men in the Paris Prospective Study, with a lowest mortality around FPG levels of 5.5 mmol/l. The DECODE (Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe) study group also found that the 7-year risk of coronary heart disease was lower in women with a fasting glucose value between 5.6 and 6.0 mmol/l compared with women with NFG (20). Because of such findings, the lower cutoff of the 2003 ADA criteria for IFG has been questioned (21,22). This reported J-shape and the results of the present study are strong reasons to reconsider the recommendation to lower the IFG cutoff to 5.6 mmol/l.

Consequences of lowering the IFG cutoff for early prediction of CVD and diabetes

The high incidence of type 2 diabetes in recent years has led to focus on the possibilities of prevention of diabetes. Indeed, lifestyle intervention studies have convincingly shown that in subjects with IGT, risk of diabetes and development of abnormal levels of cardiovascular risk factors could be reduced (23–25). However,

the IFG5.6 group includes a very large, relatively healthy group of subjects with a different metabolic profile than IGT subjects. It is questionable if prevention strategies would be similarly effective in IFG as in IGT subjects with high risk of developing diabetes. In the present study, one-third of the population would be classified as IFG5.6, while the risk of developing diabetes is lower and the CVD mortality risk is similar to that of NFG subjects. The fact that high CVD mortality risk is only present in those subjects who will develop diabetes within 6 years indicates that our focus should lie on treatment of CVD risk factors and early detection of diabetes.

References
1. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part I. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 15:539–553, 1998
2. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. The DECODE-study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic Criteria in Europe. *Diabetologia* 42:647–654, 1999
3. de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ: Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the

Hoorn Study. *JAMA* 285:2109–2113, 2001

4. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 20:1183–1197, 1997

5. Genuth S, Alberti KGMM, Bennett P, Buse J, DeFronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P: Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care* 26:3160–3167, 2003

6. Qiao Q, Jousilahti P, Eriksson J, Tuomilehto J: Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up. *Diabetes Care* 26:2910–2914, 2003

7. Mooy JM, Grootenhuis PA, de Vries H, Valkenburg HA, Bouter LM, Kostense PJ, Heine RJ: Prevalence and determinants of glucose intolerance in a Dutch Caucasian population: the Hoorn Study. *Diabetes Care* 18:1270–1273, 1995

8. Seidell JC, Cigolini M, Charzewska J, Contaldo F, Ellsinger B, Bjorntorp P: Measurement of regional distribution of adipose tissue. In *Obesity in Europe.* Bjorntorp P, Rossner S, Eds. London, John Libbey, 1988, p. 351–357

9. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 18:499–502, 1972

10. World Health Organization: *International Classification of Diseases, Ninth Edition.* Vols. 1 and 2. Geneva, World Health Organization, 1977

11. Kannel WB, Plehn JF, Cupples LA: Cardiac failure and sudden death in the Framingham Study. *Am Heart J* 115:869–875, 1988

12. Borch-Johnsen K, Colagiuri S, Balkau B, Glumer C, Carstensen B, Ramachandran A, Dong Y, Gao W: Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. *Diabetologia* 47:1396–1402, 2004

13. Davidson MB, Landsman PB, Alexander CM: Lowering the criterion for impaired fasting glucose will not provide clinical benefit. *Diabetes Care* 26:3329–3330, 2003

14. Vaccaro O, Riccardi G: -to: Borch-Johnsen K, Colagiuri S, Balkau B et al: (2004) Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. *Diabetologia* 47:1396–1402. *Diabetologia* 47:2047–2048, 2004

15. Fontbonne A, Eschwege E, Cambien F, Richard JL, Ducimetiere P, Thibult N, Warnet JM, Claude JR, Rosselin GE: Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. *Diabetologia* 32:300–304, 1989

16. Jarrett RJ: The cardiovascular risk associated with impaired glucose tolerance. *Diabet Med* 13 (Suppl. 2):S15–S19, 1996

17. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. *Diabetes Care* 22:920–924, 1999

18. de Vegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ: Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. *Diabetologia* 42:926–931, 1999

19. Balkau B, Bertrais S, Ducimetiere P, Eschwege E: Is there a glycemic threshold for mortality risk? *Diabetes Care* 22:696–699, 1999

20. DECODE Study Group, the European Diabetes Epidemiology Group: Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? *Diabetes Care* 26:688–696, 2003

21. Dekker JM, Balkau B: Counterpoint: impaired fasting glucose: the case against the new American Diabetes Association guidelines. *Diabetes Care* 29:1173–1175, 2006

22. Forouhi NG, Balkau B, Borch-Johnsen K, Dekker J, Glumer C, Qiao Q, Spijkerman A, Stolk R, Tabac A, Wareham NJ: The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group. *Diabetologia* 49:822–827, 2006

23. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 346:393–403, 2002

24. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. *Diabetes Care* 20:537–544, 1997

25. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 344:1343–1350, 2001